Pharmacogenomic panel testing for personalized supportive oncology

Abstract Purpose Drug response for cancer symptom management is variable. The purpose of this trial is to study the impact of multigene pharmacogenomic (PGx) testing on drug prescribing in supportive oncology. Methods This is a single-arm prospective trial of adults with cancer referred to the supportive oncology clinic with Edmonton Symptom Assessment System pain ≥ 4, depression ≥ 3, or requiring antidepressant modification. Patients were genotyped for variants in CYP3A4 , CYP3A5 , CYP2D6 , CYP2C9 , CYP2C19 , CYP2B6 , COMT , OPRM1 , SLC6A4 , and HTR2A , and assessed every 4 weeks up to a maximum of 16 weeks. Primary endpoint was the proportion of patients with ≥ 1 PGx-guided intervention. Secondary endpoints included the type/frequency of drug-gene interactions (DGIs) at baseline and final visits, and the type/frequency of interruptive PGx alerts in the electronic health record (EHR). Results 70 patients were genotyped (54% female, 67% White, 33% Black, median age 59). Gynecologic (21%), breast (14%), and hematologic (14%) cancers were most common, and 64% had stage III or IV disease. 50% and 59% carried a CYP2D6 or CYP2C19 non-normal metabolizer phenotype, respectively. Of 66 evaluable patients, 9 (14%, 95% CI 7–24%) had a PGx-guided intervention, mostly for opioids and antidepressants. At baseline and final visits, 25 (n = 23; 35%) and 22 (n = 21; 32%) DGIs, respectively, were present. There were 26 interruptive alerts triggered for 10 (18%) of 56 patients evaluable for PGx alerts, mostly for CYP2C19-proton pump inhibitors (PPIs) and CYP2C19/CYP2B6-antidepressants. Conclusion DGIs, mostly for opioids, antidepressants, and PPIs, were common and PGx-guided interventions occurred in a minority of patients. Interruptive alerts were frequent and prompted PGx-guided interventions in most patients with actionable interactions, highlighting the opportunity to optimize EHR-based clinical decision support.

Authors

Institutions

Publication Details

Journal
Supportive Care in Cancer
Published
2026-11-17
DOI
https://doi.org/10.1007/s00520-026-11489-x
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacogenomic panel testing for personalized supportive oncology

Nury Steuerwald, Jai Narendra Patel, Declan Walsh, Danielle M. Boselli et al.
Supportive Care in Cancer
Pharmacogenetics and Drug Metabolism
article

Pharmacogenomic panel testing for personalized supportive oncology

Nury Steuerwald, Jai Narendra Patel, Declan Walsh, Danielle M. Boselli, James Thomas Symanowski, Alicia Trynor Hamilton, Kunal C. Kadakia, Sarah Morris, D. Grace Nguyen, Mathew Smith
article en

Abstract

Abstract Purpose Drug response for cancer symptom management is variable. The purpose of this trial is to study the impact of multigene pharmacogenomic (PGx) testing on drug prescribing in supportive oncology. Methods This is a single-arm prospective trial of adults with cancer referred to the supportive oncology clinic with Edmonton Symptom Assessment System pain ≥ 4, depression ≥ 3, or requiring antidepressant modification. Patients were genotyped for variants in CYP3A4 , CYP3A5 , CYP2D6 , CYP2C9 , CYP2C19 , CYP2B6 , COMT , OPRM1 , SLC6A4 , and HTR2A , and assessed every 4 weeks up to a maximum of 16 weeks. Primary endpoint was the proportion of patients with ≥ 1 PGx-guided intervention. Secondary endpoints included the type/frequency of drug-gene interactions (DGIs) at baseline and final visits, and the type/frequency of interruptive PGx alerts in the electronic health record (EHR). Results 70 patients were genotyped (54% female, 67% White, 33% Black, median age 59). Gynecologic (21%), breast (14%), and hematologic (14%) cancers were most common, and 64% had stage III or IV disease. 50% and 59% carried a CYP2D6 or CYP2C19 non-normal metabolizer phenotype, respectively. Of 66 evaluable patients, 9 (14%, 95% CI 7–24%) had a PGx-guided intervention, mostly for opioids and antidepressants. At baseline and final visits, 25 (n = 23; 35%) and 22 (n = 21; 32%) DGIs, respectively, were present. There were 26 interruptive alerts triggered for 10 (18%) of 56 patients evaluable for PGx alerts, mostly for CYP2C19-proton pump inhibitors (PPIs) and CYP2C19/CYP2B6-antidepressants. Conclusion DGIs, mostly for opioids, antidepressants, and PPIs, were common and PGx-guided interventions occurred in a minority of patients. Interruptive alerts were frequent and prompted PGx-guided interventions in most patients with actionable interactions, highlighting the opportunity to optimize EHR-based clinical decision support.

Supportive Care in CancerVol. 34(12)
Atrium Health Wake Forest Baptist (US), Levine Cancer Institute (US), Wake Forest Baptist Comprehensive Cancer Center (US), Wake Forest University (US)
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon